drugset / Trial / NCT05493462
Intranasal Human FGF-1 for Subjects With Parkinson's Disease
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, pilot study to evaluate the safety, tolerability and efficacy of two dose levels of human FGF-1 administered intranasally to subjects with Parkinson's disease. A low dose of 450 µg FGF-1 (6 µg/kg for a 75 kg subject) and a high dose of 900 µg FGF-1 (12 µg/kg for a 75 kg subject) will be studied sequentially.
Timeline
- Start
- 2022-09
- Primary completion
- 2022-12
- Completion
- 2022-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FGF-1 | Protein / enzyme biologic | 450 ug | — |
| Subject | FGF-1 | Protein / enzyme biologic | 900 ug | — |